Cirrhosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Line 5: | Line 5: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
The following therapies are under trial: | The following therapies are under trial: | ||
*[[Obeticholic acid]] (OCA) for patients with [[primary biliary cirrhosis]]. | *[[Obeticholic acid]] (OCA) for patients with [[primary biliary cirrhosis]].<ref name="pmid21297469">{{cite journal| author=Lindor KD| title=Farnesoid X receptor agonists for primary biliary cirrhosis. | journal=Curr Opin Gastroenterol | year= 2011 | volume= 27 | issue= 3 | pages= 285-8 | pmid=21297469 | doi=10.1097/MOG.0b013e32834452c8 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21297469 }} </ref> | ||
==Reference== | ==Reference== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 18:29, 6 September 2012
Cirrhosis Microchapters |
Diagnosis |
---|
Treatment |
Case studies |
Cirrhosis future or investigational therapies On the Web |
American Roentgen Ray Society Images of Cirrhosis future or investigational therapies |
Risk calculators and risk factors for Cirrhosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-In-Chief: Ujjwal Rastogi, M.B.B.S. [2]
Overview
Future or Investigational Therapies
The following therapies are under trial:
- Obeticholic acid (OCA) for patients with primary biliary cirrhosis.[1]
Reference
- ↑ Lindor KD (2011). "Farnesoid X receptor agonists for primary biliary cirrhosis". Curr Opin Gastroenterol. 27 (3): 285–8. doi:10.1097/MOG.0b013e32834452c8. PMID 21297469.